Drug Profile
PVX 009
Alternative Names: PVX-009Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator PepVax, Inc.
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in USA (Parenteral)
- 06 Mar 2018 PepVax files a provisional patent application with the US Patent and Trademark Office for SMARTmid™ DNA platform technology in USA
- 05 Jan 2018 PepVax intends to file an IND application for PVX 009 in the mid of 2019